Abcam, ab264501, Ramucirumab ELISA Kit

Size: 1 x 96Tests
Ramucirumab ELISA Kit is a Quantitative ELISA for the measurement of Ramucirumab in Human in Biofluids samples.
Key facts
Detection method:Colorimetric,
Sample types:Plasma, Serum,
Reacts with:Human,
Assay type:Quantitative,
Sensitivity:= 20 ng/mL,
Range:20 - 600 ng/mL,
Assay Platform:Microplate

Product details:
Note: Ramucirumab ELISA kit ab264501 is intended for Research Use Only, not for use in diagnostic procedures.
This kit is a sandwich based ELISA kit. The color developed is proportional to the amount of Ramucirumab in the sample or standard. Results of samples can be determined directly using the standard curve.
This product is manufactured by BioVision, an Abcam company and was previously called E4698 BioSim™ Ramucirumab (Human) ELISA Kit. E4698-100 is the same size as the 1 x 96 tests size of ab264501.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Ramucirumab is a monoclonal antibody that targets vascular endothelial growth factor receptor 2 (VEGFR-2). It specifically binds to the extracellular domain of VEGFR-2 inhibiting its ability to interact with its natural ligands. VEGFR-2 has a mass of around 150 kDa and is primarily expressed on endothelial cells which line the blood vessels. Ramucirumab acts by blocking angiogenic signals which are critical for new blood vessel formation.
Biological function summary
VEGFR-2 is an important component in the angiogenesis process which is the formation of new blood vessels from pre-existing ones. It is part of the plasma membrane-spanning receptor tyrosine kinase family. Upon ligand binding VEGFR-2 undergoes dimerization and autophosphorylation activating downstream signaling pathways. These pathways promote endothelial cell proliferation migration and survival. VEGFR-2's role in vessel permeability and inflammation also contributes to its biological significance.
Pathways
VEGFR-2 is integral within the VEGF signaling pathway and endothelial cell signaling pathways. It closely interacts with vascular endothelial growth factor A (VEGF-A) as its main ligand. This interaction triggers a cascade involving phosphatidylinositol-3-kinase (PI3K) and mitogen-activated protein kinases (MAPK) which are important for vascular development and maintenance. VEGFR-2's activity is balanced by its relation to other receptors like VEGFR-1 ensuring proper vessel formation and function.
Ramucirumab has shown effectiveness for conditions such as gastric cancer and colorectal cancer. These diseases often exhibit abnormal angiogenesis which is important for tumor growth and metastasis. VEGFR-2 is upregulated in these cancers making it a target for therapeutic intervention. Ramucirumab's binding to VEGFR-2 prevents VEGF-mediated tumor vascularization and progression. Its relationship with other proteins such as fibroblast growth factor receptors (FGFRs) in cancer highlights the complexity of angiogenic signaling in malignancies.